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Purpose: There are no internationally agreed upon clinical
guidelines as to which women with gynecological cancer would
benefit from Lynch syndrome screening or how best to manage the
risk of gynecological cancer in women with Lynch syndrome.
The Manchester International Consensus Group was convened in
April 2017 to address this unmet need. The aim of the Group was
to develop clear and comprehensive clinical guidance regarding
the management of the gynecological sequelae of Lynch syndrome
based on existing evidence and expert opinion from medical
professionals and patients.
Methods: Stakeholders from Europe and North America worked
together over a two-day workshop to achieve consensus on best
practice.
Results: Guidance was developed in four key areas: (1) whether
women with gynecological cancer should be screened for Lynch
syndrome and (2) how this should be done, (3) whether there was
a role for gynecological surveillance in women at risk of Lynch
syndrome, and (4) what preventive measures should be recom-
mended for women with Lynch syndrome to reduce their risk
of gynecological cancer.
Conclusion: This document provides comprehensive clinical
guidance that can be referenced by both patients and clinicians
so that women with Lynch syndrome can expect and receive
appropriate standards of care.
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0489-y
Keywords: Lynch syndrome; endometrial cancer; screening;
surveillance; guidance
INTRODUCTION
Lynch syndrome is an autosomal dominantly inherited cancer
syndrome including colorectal (CRC), endometrial (EC), and
ovarian cancer (OC).1 It is caused by pathogenic variants of the
DNA mismatch repair (MMR) system genes MLH1, MSH2,
MSH6, and PMS2, which prevent the correction of acquired
errors during DNA synthesis. Gynecological cancers are often
the sentinel Lynch syndrome event in women and have an
excellent prognosis.2 This provides an opportunity to diagnose
women before further oncological sequelae affect them or their
family. Early diagnosis allows women to be enrolled in cancer
surveillance programs and enables cascade testing for at-risk
relatives. There is well-documented survival advantage for those
with Lynch syndrome who are compliant with CRC surveil-
lance.3 Further, early identification of Lynch syndrome can
enable the uptake of cancer prevention strategies, including
aspirin and risk-reducing surgery.4,5 A timely diagnosis may
also have cancer prognosis and treatment implications. For
example, MMR-deficient tumors are susceptible to immune
checkpoint inhibition through PD-1 blockade.6 These con-
siderations necessitate guidelines to direct the identification and
care of individuals affected by Lynch syndrome. Although CRC
clinical guidance is widely available, the same is not true for
gynecological cancers (eTable 1). The lack of comprehensive
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guidance has led to a nonuniform approach to management
of women with Lynch syndrome globally. The aim of the
Manchester International Consensus Meeting was to provide
the first gynecological-specific guidance for the diagnosis,
prevention, and surveillance of Lynch syndrome–associated
gynecological malignancies.
The Manchester International Consensus Meeting 2017 for
the management of gynecological cancers in Lynch
syndrome
The meeting was held on 24–25 April 2017. Fifty stakeholders
attended from across Europe and North America, including
patients (n= 2), patient support group representatives (n=
2), gynecological oncology surgeons (n= 12), gynecology
nurse specialists (n= 5), clinical geneticists (n= 10), genetic
counselors (n= 2), medical oncologists (n= 1), colorectal
surgeons (n= 2), gastroenterologists (n= 1), histopatholo-
gists (n= 10), genetic pathologists (n= 1), health economists
(n= 1), and epidemiologists (n= 1).
Preparation for the meeting included a systematic review
of the literature to identify key papers to inform discussion.
A systematic review with meta-analysis was performed
to provide a robust estimate of the prevalence of Lynch
syndrome in women with endometrial cancer, using the
methodology described in our published protocol.7 The body
of literature identified through this search also enabled
informed discussion regarding the comparable utility of
MMR immunohistochemistry (IHC), microsatellite instability
(MSI), MLH1 methylation testing, and direct germline
sequencing for pathological variants of the MMR genes by
next-generation sequencing (NGS) for Lynch syndrome
testing (eTable 2). An identical search was conducted in
parallel, substituting the Medical Subject Heading (MeSH)
term “endometrial” with “ovarian.” Further searches to
identify evidence for risk-reducing interventions and the
clinical effectiveness of gynecological surveillance in Lynch
syndrome (eTable 3) were conducted. Key studies were
identified by abstract review and graded according to the
category of evidence they achieved (Table 1). Potential bias
was assessed by two reviewers, and discrepancies settled by a
third, as previously described;7 those studies with a high
likelihood of bias were excluded. Papers identified through
these searches were grouped according to the four clinical
questions detailed in this document, and sent to the expert
assigned as question lead before the meeting.
At the meeting, day 1 consisted of 11 lectures covering the
prevalence of Lynch syndrome and its associated cancer risks,
the patient’s perspective, the process of developing clinical
guidance, lessons learned from the colorectal community,
current diagnostic technologies, and methods of gynecological
surveillance. These lectures provided a critical review of the
studies identified through the systematic searches described
above and had the purpose of providing the consensus group
with up-to-date evidence on which to base its recommenda-
tions. Participation was encouraged when assessing the
quality of the available evidence during the lectures.
The second day rotated delegates through working groups
focused on screening for Lynch syndrome in gynecological
cancer, diagnostic methods for such screening, the role of
risk-reducing surgery and gynecological surveillance. Each
group benefited from multidisciplinary health-care profes-
sional and lay representation. Topics were debated until an
agreed statement could be reached. The precise wording of
these statements was decided through careful deliberation
until unanimous agreement was confirmed by a show of
hands. Once all delegates had rotated through the four focus
groups, a final forum enabled group chairpersons to feed
back where consensus had been reached. A further show of
hands was required for individual statements to reach this
consensus document. The document was written and edited
by the expert writing group and circulated through all authors
until each recommendation was ratified. The levels of
recommendation are shown in Table 2.
Question 1: Should women with gynecological cancer be
screened for Lynch syndrome? (Box 1)
One in 279 of the general population carry pathogenic
variants in one of the MMR genes, of which the vast majority
are unaware.8 Approximately 1 in 30 CRCs are Lynch
syndrome associated.9 The proportion of ECs that are Lynch
syndrome associated is around 1 in 30, but estimates are
based on small studies hampered by methodological limita-
tions. The largest of these (n > 300) are shown in eTable 2.
Current UK guidance from the National Institute for Health
and Care Excellence (NICE) supports the universal screening
of CRC for Lynch syndrome.10 Given similar rates of Lynch
syndrome in EC and CRC, and the potential to reduce
mortality through colorectal surveillance and cascade testing
of relatives, the Consensus Group strongly recommends that
women with EC should also be screened for Lynch syndrome.
Restricting screening to those with a higher pretest
probability of Lynch syndrome (e.g., younger patients) is
likely to reduce the resource burden, although at the cost of
missing more Lynch syndrome cases. One study found only
25% of IHC MMR-deficient tumors were in women <50
years.11 Hampel et al. found 20% of proven Lynch cases
presented >60 years.12 While older patients may have a lower
risk of Lynch syndrome, and less potential to benefit from
Table 1 Grading of evidence
Grading of evidence
Category of evidence Grading of evidence
Traditional Guideline
Meta-analysis of randomized controlled trials Ia A
Randomized controlled trials Ib A
Well-designed and controlled study without
randomization
IIa B
Well-designed quasi-experimental study IIb B
Nonexperimental descriptive study III B
Expert opinion IV C
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risk-reducing measures, they may also have younger relatives
who could benefit from the identification of family pathogenic
variants. Further, targeted screening has its own challenges,
particularly that screening is not conducted despite being
indicated.
Amsterdam-II and Bethesda criteria are family
history–based prediction tools designed to target Lynch
syndrome screening in CRC. Extrapolation of these tools to
EC has shown specificity of 61% and 49% for Amsterdam-II
and Bethesda criteria, respectively.13 Newer prediction tools,
MMRpredict1,26, MMRpro, and PREMM5, have increased
sensitivity and specificity.14–16 However, they rely on accurate
family self-reported history being recorded by the clinician. A
quality-controlled family history is time consuming, outside
the scope of many busy clinical settings, and does not meet
the specificity or sensitivity needed for a first-line test to
identify MMR pathogenic variant carriers,17 however, in the
absence of tumor material, such prediction models can be
useful to guide germline testing.
Restricting Lynch syndrome screening to tumors with
certain pathological phenotypes, for example endometrioid or
clear cell morphology, tumors of the lower uterine segment,
and those with heavy infiltrates of tumor-associated T-
lymphocytes, has not been tested prospectively as a means to
direct Lynch syndrome screening.18 A low body mass index
(BMI) increases the likelihood of Lynch syndrome being the
underlying cause in EC.19 In CRC, restricting screening for
Lynch syndrome to certain high-risk pathological features is
not sufficiently sensitive.20
With regard to Lynch syndrome–associated OC, there is
minimal evidence to guide clinical care. A single-center study
found 21% of nonserous epithelial OC to be MMR deficient
by IHC.21 Lynch syndrome–associated OC is predominantly
endometrioid, presenting at an earlier age and stage than
sporadic OC, with improved survival rates.22 Lynch syndrome
is found in 7% of women with synchronous EC and OC.23
Many professional organizations now recommend testing all
epithelial OC patients for BRCA1/2 pathological variants.24,25
Given the similar cumulative risk of OC in Lynch syndrome,
testing premenopausal women with epithelial OC for both
BRCA1/2 and Lynch syndrome is appropriate. This is even
more persuasive in an era of panel gene testing where there is
no additional cost to add more genes.
There is no evidence to support a link between Lynch
syndrome and other gynecological cancers, neither myome-
trial, nor squamous cancers of the vulva, vagina, or cervix, in
which the most important etiological driver is persistent
infection with high-risk human papillomavirus (HPV). Thus
screening for Lynch syndrome in women affected by cancers
of the lower genital tract is not recommended, with the
exception of (HPV-independent) endocervical adenocarcino-
mas, given the difficulty of distinguishing them from lower
uterine segment endometrial cancers.26
Question 2: How should women with gynecological cancer
be screened for Lynch syndrome? (Box 2)
Screening women with gynecological cancer for Lynch
syndrome is a multidisciplinary responsibility. Health-care
Table 2 Levels of recommendation
Level Description Rationale
Strongly
recommend
Patients should expect this level of care Unanimous agreement from the consensus members. Level of evidence is
thought to be sufficient to make this recommendation.
Recommend Care providers and stakeholders should aim to
provide this level of care
Unanimous agreement from the consensus members. Level of evidence is
supports the recommendation but is not conclusive.
Neutral Care providers and stakeholders may wish to
provide this service
No unanimous agreement and evidence inconclusive.
Box 1. Consensus recommendations for screening women with gynecological cancer for Lynch syndrome
Where resources are available, the Consensus Group strongly recommends universal screening of endometrial cancer for Lynch syndrome
(grade B).
Where resources are restricted, the Consensus Group strongly recommends screening for Lynch syndrome in endometrial cancer where
•Women are diagnosed at 60 years of age or younger (grade B).
•Women diagnosed at any age have one or more of the following risk factors: a personal history of metachronous or synchronous Lynch
syndrome–associated cancer, a first-degree relative with Lynch syndrome–associated cancer at 60 years of age or younger, pathological
features strongly suggestive of a Lynch syndrome–associated cancer (grade B).
The Consensus Group recommends screening for Lynch syndrome in ovarian cancer where
•Women are diagnosed at 50 years of age or younger (grade C).
•Women diagnosed at any age have nonserous and nonmucinous histology (grade C).
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systems require robust procedures for quality-assured tumor
testing and communication of results. Tissue analysis to triage
women for Lynch syndrome testing highlights the potential of
having Lynch syndrome rather than diagnosing it. Further-
more, identifying MMR-defective status provides important
prognostic information and can direct, for example, immu-
notherapy treatment strategies.27 Thus, MMR IHC/MSI
testing should form part of standard patient care and prior
consent is not required. When germline testing is recom-
mended, informed consent should be sought and patients are
entitled to receive specialist counseling.
Four options were explored for the initial screening of
tumor samples for Lynch syndrome: MSI, IHC with
methylation testing, MSI with IHC and/or methylation
testing, and germline NGS (Fig. 1). NGS is the gold standard
for identifying somatic pathogenic variants in MMR genes;
there remain challenges in working with formalin-fixed
paraffin-embedded tumor samples, but performance of NGS
on such samples is improving.28 It should be noted that exon
panel NGS will not identify MLH1 silencing due to
methylation.29 Sequencing of PMS2 is problematic due to
the presence of numerous pseudogenes.30 NGS is expensive
and many hospitals have limited access to it. Thus most
studies and current clinical practice employ a screening
triage with the use of IHC and/or MSI before germline NGS
and large rearrangement testing (eTable 2).
There is good concordance between MSI and IHC
analysis.31,32 Where there is discordance this may, for
example, reflect MSI secondary to POLE pathogenic variants,
heterogeneity of MMR loss within the tumor, or microsatellite
stable (MSS) MSH6 or PMS2 loss.32,33 The first is important
because POLE pathogenic variants have prognostic implica-
tions; the last because MSI triage may miss Lynch syndrome
cases due to MSH6 pathogenic variants.34 For IHC, sensitivity
and specificity range between 86–100% and 48–67%,
respectively.19,35,36 For MSI, sensitivity and specificity are
similar at 77–100% and 38–81% (refs. 19,35,36). Where there
is a strong family history and where EC/OC presents under
the age of 50 years with normal IHC and/or MSI, there is
still an argument for definitive NGS.37 Investigations should
be performed in an agreed stepwise and protocol-driven
manner.10
IHC analysis has the advantage of identifying the specific
protein that has been lost, thus indicating the potentially
mutated gene. Furthermore, some pathogenic variants in
MSH6 have been shown to associate with tumor MSS.38 The
identification of MLH1 protein loss enables methylation
analysis, which can exclude women with somatic MLH1 loss
from unnecessary NGS.38 Methylation-specific polymerase
chain reaction (PCR) is simple and cost-effective, however
validation work has been almost exclusively in the CRC
population.39,40 Methylation-specific PCR is not widely
Box 2. Consensus recommendations for the methodology used to screen women with gynecological cancer for Lynch syndrome
The Consensus Group strongly recommends that quality-assured processes for the identification, screening, and reporting of tests for Lynch
syndrome are piloted and audited before they are implemented at a local level (grade B).
The Consensus Group strongly recommends that tumor MMR or MSI status is used to identify women for germline MMR testing. There is
no evidence to advocate MSI over MMR immunohistochemistry or vice versa (grade B).
Where MMR immunohistochemistry is performed, the Consensus Group recommends testing for all four MMR proteins using formalin-
fixed paraffin-embedded biopsy or resected tumor specimens (grade B).
The Consensus Group strongly recommends that immunohistochemistry testing is tightly regulated and protocol-driven to ensure
interpretable, quality-assured results that can be understood by nonspecialist clinicians (grade C).
Where MLH1 protein loss is identified or initial screen suggests microsatellite instability high (MSI-H), the Consensus Group recommends
the use of promoter methylation-specific PCR to identify probable cases of MLH1 silencing and therefore further filter the number of
samples requiring NGS, while noting that a small proportion of such cases are due to constitutional methylation or pathogenic variants
involvingMLH1 (grade B). BRAF immunohistochemistry or sequencing cannot be used as a proxy for somatic MLH1 hypermethylation in
gynecological cancers (grade B).
For ovarian cancer, the Consensus Group strongly recommends somatic NGS on formalin-fixed paraffin-embedded or fresh frozen tumor
tissue of nonmucinous invasive epithelial tumors, which should include BRCA1/2 and Lynch syndrome genes (grade B/C).
The Consensus Group strongly recommends that explicit patient consent is sought before germline testing (grade C).
The Consensus Group strongly recommends appropriate referral pathways are established with Clinical Genetics before screening is
initiated. This includes those with a positive triage test who are negative for a germline Lynch syndrome pathogenic variant (grade B/C).
Where tumor tests suggest Lynch syndrome but there is no Lynch syndrome–associated pathogenic variant on germline NGS, the
Consensus Group recommends that clinicians seek to establish the existence of other somatic or germline pathogenic variants, such as
biallelic MuTYH, POLE, and/or double somatic MMR pathogenic variants, which may have prognostic implications (grade B).
All recommendations are based on current technology. As this evolves so should clinical practice.
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available, with only specialist laboratories offering this test.
The molecular mechanism for the strong association of BRAF
variant with CRC harboring somatic MLH1 hypermethylation
is incompletely understood but appears to be tissue/tumor-
specific; unlike algorithms in use for CRC, BRAF immuno-
histochemistry or sequencing cannot be used as a proxy for
somatic MLH1 hypermethylation in gynecological cancers,
as oncogenic BRAF variants occur so rarely in these.41
Therefore, moving straight to germline NGS on the basis of
IHC MLH1 loss is also an option, although an expensive one.
The MMR proteins form heterodimers, with MLH1 pairing
with PMS2 and MSH2 pairing with MSH6. These proteins are
unstable in their unpaired state, and while MLH1 and MSH2
can form stable heterodimers with other proteins, PMS2 and
MSH6 can only dimerize with MLH1 and MSH2 respectively.
It has therefore been proposed that IHC analysis can be
performed by testing only two of the four MMR proteins,
PMS2 and MSH6, because loss of MLH1 and MSH2 leads to
loss of their heterodimer partner (PMS2 and MSH6
respectively).42 However, the accuracy of this system is
unproven in gynecological cancers.43 The interpretation of
stained slides requires an experienced senior clinician, and
IHC more frequently needs to be repeated due to unin-
terpretable staining patterns in EC compared with CRC.44
Furthermore, the effect of neoadjuvant treatment on tissue
analysis for MMR dysfunction has not been defined in EC.45
A reporting proforma is shown in eFigure 1. The continuing
use of tightly regulated and high quality IHC protocols should
be assured by laboratory participation in a national or
international external quality assurance scheme that covers
both IHC methods and interpretation.
A testing strategy using IHC and MLH1 methylation is
likely to be more cost-effective than strategies using MSI
testing (because MLH1 methylation must be conducted on
all MSI tumors) and strategies not using MLH1 methylation
(because methylation testing is cheaper than NGS and
excludes a significant proportion of sporadic cases). Docu-
mented IHC results can also help interpret NGS results.
Endometrial cancer
Immunohistochemistry testing for MLH1, MSH2, MSH6 and
PMS2 proteins# and/or testing for microsatellite instability
MLH1 protein absent (with or
without loss of PMS2 protein)
MLH1
promoter
methylation
Hyper-methylatedNormal
MSH2, MSH6 or PMS2 protein
absent MSI-H without MMR IHC loss*
Germline testing for Lynch syndrome-associated mutations
Not Lynch syndrome
No protein loss or MSS/MSI-L
Not Lynch syndrome
Fig. 1 Proposed diagnostic schema of endometrial cancer screening for Lynch syndrome. Consent should be sought from the patient before germline
testing. #We recognize the possibility of using a two protein screen using PMS2 and MSH6 initially, however the evidence base is not definitive. *If only
microsatellite testing used without immunohistochemistry then all those found to be MSI-H should either be further triaged with methylation testing or
undergo direct germline analysis. IHC immunohistochemistry, MSI-H microsatellite instability high, MSI-L microsatellite instability low, MMR mismatch repair,
MSS microsatellite stable.
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Question 3: Is there a role for gynecological surveillance
in women at risk of Lynch syndrome? (Box 3)
Many female MMR pathogenic variant carriers opt to
undergo gynecological surveillance in lieu of, or whilst
awaiting, risk-reducing surgery. The aim of surveillance is to
detect premalignant disease or early stage cancer, with the
ultimate aim of improving morbidity and mortality from the
malignant gynecological sequelae of Lynch syndrome.
The data relating to gynecological surveillance in Lynch
syndrome are generally of low quality, with single-center,
retrospective studies predominating (eTable 3). Some studies
show benefit and others show no benefit of gynecological
surveillance in the early detection of endometrial cancer.46
Survival data are limited and mortality data are lacking.
However, both preinvasive (atypical hyperplasia) and stage 1
disease have been diagnosed in asymptomatic women under-
going EC surveillance (eTable 3). One study found that
women who were not under surveillance were more likely to
die from their EC than those in surveillance, although this did
not reach statistical significance. In addition, three cancers
were “missed” in the surveillance group.47 Another found
a high proportion of interval ECs in women undergoing
surveillance (6/13) (ref. 48). It is important to note that EC
survival rates in women with Lynch syndrome are extremely
good, with 10-year survival of 98% in those undergoing
surveillance;3 comparative data for LS-EC in women not
undergoing surveillance are not available.
The Consensus Group acknowledged that ultrasonogra-
phy, biopsy, and hysteroscopy could detect EC and
premalignant pathological abnormalities. However, there
is no evidence that this leads to a stage shift or improved
survival in women with Lynch syndrome–associated EC.
Furthermore, many patients identified during gynecological
surveillance are symptomatic of endometrial pathology
(eTable 3). Patient representatives in the Group were strong
advocates of gynecological surveillance as a means of regular
review and reassurance. Therefore the Consensus Group
supported a discussion with individual women as to whether
they would wish an annual appointment to undergo detailed
symptom inquiry, a rediscussion regarding the option for
risk-reducing hysterectomy and bilateral salpingo-
oophorectomy and the timing of this, as well as a holistic
review of a woman’s contraceptive and fertility needs, and
advice regarding cancer risk-reducing behaviors. Women with
red flag symptoms of gynecological cancer, including
abnormal bleeding, weight loss, bloating, change in bowel
habit, recurrent urinary symptoms, and abdominal pain
should undergo targeted investigations for gynecological
pathology.49,50 The Consensus Group was strongly supportive
of the need for rapid access facilities being available for
women with Lynch syndrome and that suspicious symptoms
or signs of malignant gynecological disease should not await
routine review in clinic.
Regarding OC, there is currently insufficient evidence that
surveillance is of benefit.46 Large randomized controlled trials
(RCTs) of general population screening for OC through
ultrasound scanning (USS) or multimodal screening (CA125
analyzed by an algorithm as a first-line test, followed by
reflex USS) have so far failed to demonstrate a statistically
significant mortality benefit.51,52 However, screening in high-
risk BRCA1/2 pathogenic variant carriers with 4-monthly
CA125 analyzed by an algorithm and reflex USS does lead to
a stage shift in the disease detected; whether this translates
into mortality benefit has yet to be established.53 Extrapola-
tion of OC screening research to the LS population is limited
by the known biological differences between LS-associated
and sporadic/BRCA1/2-associated OC.54
Whilst there is true equipoise in the literature, high quality
research regarding the value of gynecological surveillance in
Lynch syndrome could be performed. The options for study
design could include a cluster RCT or a centralized repository
for routine data collection from local surveillance programs.
Studies should be adequately powered to determine whether
surveillance picks up earlier disease with benefits for patient
outcomes, as well as assessing its psychological impact and
cost-effectiveness.
Box 3. Consensus recommendations for gynecological surveillance in women at risk of Lynch syndrome
The Consensus Group strongly recommends that all women be informed of their MMR pathogenic variant-specific risk of gynecological
cancer, specifically endometrial and ovarian cancer, interpreted in the context of their family history (grade C).
The Consensus Group recommends that women at risk of Lynch syndrome who have not experienced gynecological cancer undergo
optional annual review from the age of 25 with an appropriate clinician to discuss red flag symptoms for endometrial and ovarian cancer,a
and where contraceptive and fertility needs are raised. A gynecological referral should be made if there is a specific need (grade C).
The Consensus Group does not recommend invasive gynecological surveillance in MMR pathogenic variant carriers (grade C), due to
insufficient evidence that this improves outcomes over symptom awareness and urgent investigation of red flag symptoms. The Consensus
Group strongly recommends further research in this area be prioritized by funding bodies. Furthermore, where good quality endometrial
cancer surveillance programs already exist, systematic collection of cancer outcomes should be undertaken.
The Consensus Group strongly recommends that women participate in routine cervical screening in line with local cervical screening
programs (grade A).
aRed flag symptoms of gynecological cancer include abnormal bleeding, weight loss, bloating, change in bowel habit, recurrent urinary
symptoms, and abdominal pain.50
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Question 4: What preventive measures should be
recommended in Lynch syndrome to reduce gynecological
cancer risk? (Box 4)
Risk-reducing total hysterectomy and bilateral salpingo-
oophorectomy prevents gynecological cancer in women at risk
of Lynch syndrome.5 Surgery is not without risk and potential
long-term side effects, however, and preoperative counseling is
important. The laparoscopic approach is associated with less
postoperative pain, quicker recovery, and improved short-term
quality of life, making it the preferred approach in uncompli-
cated cases, where resources permit.55 Surgical menopause
follows risk-reducing oophorectomy in premenopausal women.
This is associated with vasomotor symptoms, urogenital dryness
and atrophy, reduced sexual function, emotional lability, and
cognitive decline, as well as increased risks of osteoporosis,
cardiovascular disease and CRC.56 Thus prescription of
estrogen-only hormone replacement therapy (HRT) until at
least natural menopause age (~ 51 years) is strongly recom-
mended to prevent these sequelae. There is some evidence that
prior hysterectomy may be associated with greater discomfort
during intubation at colonoscopy, and lower cecal intubation
rates.57 Thus it has been suggested that women undergoing
colonoscopic surveillance following hysterectomy undergo
specific preprocedure counseling and measures to reduce
procedural discomfort.58
There are good quality prospective data outlining the cancer
risk associated with specific pathogenic variants and the age at
which these occur.59 A woman’s personal risk should be used
to provide individualized counseling regarding the need for
risk-reducing surgery and the optimal timing of this.
Box 4. Consensus recommendations for gynecological cancer risk reduction in Lynch syndrome
The Consensus Group strongly recommends that risk-reducing total hysterectomy and bilateral salpingo-oophorectomy is offered no earlier
than 35–40 years of age following completion of childbearing, in proven MLH1, MSH2, and MSH6 pathogenic variant carriers (grade B).
A woman’s personal risk should be used to provide individualized counseling regarding optimal timing of the procedure. The strength
of evidence is insufficient to strongly recommend risk-reducing surgery in PMS2 pathogenic variant carriers.
The Consensus Group strongly recommends high quality preoperative multidisciplinary counseling supplemented by patient-friendly
written information regarding the risks and benefits of risk-reducing surgery (grade C).
The Consensus Group recommends preoperative endometrial biopsy and pelvic ultrasound to identify occult gynecological cancer,
particularly if a woman is symptomatic (grade C).
The Consensus Group strongly recommends that women who are not up-to-date with colorectal surveillance are offered colonoscopy at the
time of their risk-reducing surgery (grade B).
The Consensus Group recommends that surgery is offered at specialist surgical center, although women at low surgical risk should be able
to choose local care (grade C).
The Consensus Group strongly recommends all pathological assessment and reporting is carried out at a specialist gynecological pathology
center and that the entire endometrium is sampled in the case of prophylactic hysterectomy (grade C).
The Consensus Group strongly recommends that women who undergo risk-reducing hysterectomy and removal of their ovaries are
offered estrogen-only hormone replacement therapy (HRT) (preferably via the transdermal route) until the natural age of the menopause
(age 51 years) or, in consultation with their specialist, until they wish to stop (grade B).
The Consensus Group recommends that risk-reducing colorectal and gynecological surgery is carried out at the same time, when indicated
and where possible (grade C).a
The Consensus Group recommends that surgery for colorectal cancer and risk-reducing hysterectomy is carried out at the same time, when
indicated and where possible (grade C).
Where risk-reducing surgery has been declined or is not yet appropriate, the Consensus Group recommends female carriers of MMR
pathogenic variants are given the opportunity to discuss their fertility and contraceptive needs with a specialist (grade C).
The Consensus Group recommends that the combined oral contraceptive pill is considered for women at risk of Lynch syndrome and
wishing contraception because it reduces endometrial and ovarian cancer risk (grade B).
The Consensus Group strongly recommends that MMR pathogenic variant carriers take aspirin chemoprevention to reduce their risk of
colorectal and other cancers (grade A), within the context of a clinical trial (e.g., CaPP3), or through discussion with their doctor.
The Consensus Group recommends that women at risk of Lynch syndrome maintain a healthy body mass index (BMI) (grade B).
The Consensus Group recommends that women eat a healthy diet, take regular exercise, do not smoke cigarettes, drink alcohol in
moderation or not at all, and avoid known carcinogens (e.g., tamoxifen) as part of maintaining a healthy lifestyle (grade B).
aRisk-reducing colorectal surgery here refers to an extended colectomy at the time of a colorectal cancer or in the event of any other benign
indication for a colonic resection such a multiple (right-sided) recurrent polyps.
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According to the Prospective Lynch Syndrome Database
(PLSD; http://www.lscarisk.org), the lifetime risk of EC in
women with MSH2, MLH1, and MSH6 pathogenic variants is
57%, 43%, and 46%, respectively. The cumulative risk of EC at
40 years of age is 2%, 3%, and 0%, respectively. Lifetime risk
for OC in women with MSH2, MLH1, and MSH6 pathogenic
variants is 17%, 10%, and 13%, respectively. The cumulative
risk of OC at 40 years of age is 4%, 3%, and 4%, respectively.59
Thus MSH6 pathogenic variant carriers may consider under-
going risk-reducing surgery after the age of 40 years, while
women with pathogenic variants in either MSH2 or MLH1
may consider risk-reducing surgery at around 35 years of age
assuming their childbearing is complete.60 Risk-reducing
surgery at 40 years of age is a cost-effective strategy.61 The
risk of gynecological cancer in PMS2 carriers is low; however,
patient representatives with PMS2 pathogenic variants felt
strongly that they should be offered risk-reducing surgery
alongside other women with Lynch syndrome.59
There is limited evidence as to how reproductive and
lifestyle factors impact on gynecological cancer risk in
Lynch syndrome. One study suggested that hormonal
influences do modulate cancer risk, however. In addition
to combined oral contraceptives, progestin-only methods
(pills, injectable, implants, or intrauterine system [IUS])
may protect, but there is little supporting evidence.62 The
POET trial looked to explore the use of the IUS for the
prevention of EC in women with Lynch syndrome. This trial
closed due to poor recruitment without results. Another
study showed an antiproliferative effect of exogenous
progesterone on the endometrium of women with Lynch
syndrome, suggesting that these agents could be useful for
the chemoprevention of EC.63 Exogenous hormones may
also protect against CRC.64
Aspirin reduces incidence of Lynch syndrome–associated
EC and other cancers.65 The main toxic effects of aspirin are
gastrointestinal. Major gastrointestinal bleeds (those requiring
transfusion) are increased in aspirin-takers with an odds ratio
(OR) of 1.5–2 (ref. 66). However, the absolute rates are small
and mainly affect older individuals. Because gastrointestinal
toxicity is dose dependent, the optimal dose for cancer risk
reduction is being explored through the CaPP3 study of 100
mg, 300 mg, or 600 mg/day (http://www.capp3.org/).
Smoking, alcohol use, and increased BMI may increase the
risk of CRC in individuals with Lynch syndrome; however,
the impact of lifestyle factors on gynecological cancer risk is
unknown. Aspirin may “normalize” EC risk in obese women
with Lynch syndrome.67 Despite lack of robust evidence,
women are advised to eat a healthy diet, avoid obesity, take
regular exercise, avoid smoking, only drink alcohol in
moderation, and avoid known carcinogens as part of
maintaining healthy lifestyles.
DISCUSSION
This is the first gynecology-focused internationally agreed-
upon clinical guideline for the care of women with or at risk
of Lynch syndrome.
Our key recommendations are as follows: (1) all stake-
holders should be informed of the impact of Lynch syndrome
on gynecological cancer risk; (2) systems should be estab-
lished to screen for Lynch syndrome in women with
endometrial cancer; (3) women at risk of Lynch syndrome
should be offered risk-reducing hysterectomy with bilateral
salpingo-oophorectomy, at a time appropriate to them; and
(4) further research is required to establish the value of
gynecological cancer surveillance in Lynch syndrome and to
explore other key areas where there is currently deficient
evidence to define appropriate standards of care. Screening for
Lynch syndrome is only recommended if effective manage-
ment exists to benefit those who screen positive.
The strength of our guidance comes from the broad and
expert medical specialty representation that forms our
Consensus Group. All relevant stakeholders, including
patients and patient advocates, were given equal voice during
discussion. Despite different perspectives and expertise, we
were able to achieve a consensus view on topics of
international importance. By focusing solely on the gyneco-
logical aspects of Lynch syndrome, we were able to provide
the most comprehensive guidelines yet for the empowerment
of both clinicians and patients. This was all achieved without
corporate sponsorship.
The major limitation of our work is the lack of robust
evidence on which to base our discussions and recommenda-
tions. It is hoped that these guidelines will provide the much-
needed impetus to inspire researchers and funders to
undertake and commission high quality research to fill these
gaps in our understanding.
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